Biologics Market to Grow at 4% CAGR by 2030 | Straits Research Insights

The global biologics market is expected to grow from USD 343 billion in 2021 to USD 506 billion by 2030, at a CAGR of 4% during the forecast period (2022–2030). Biologics are a category of drugs that are derived from living organisms or their products. They include a wide range of products such as monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. The rapid growth of the biologics market can be attributed to the increasing prevalence of chronic diseases, advancements in biotechnological processes, and rising investments in the development of new biologic drugs.

Biologics are widely used in the treatment of cancer, autoimmune diseases, and various genetic disorders. Their ability to target specific components of the immune system or the disease mechanism has revolutionized treatment options for patients. The biologics market has also benefited from regulatory advancements and an increasing number of biologic drugs gaining approval for commercial use, further fueling market expansion.

Market Definition

The biologics market refers to the sector that focuses on the development, production, and commercialization of biologic products. Biologics are large, complex molecules made from living organisms and include a variety of products, such as monoclonal antibodies, therapeutic proteins, vaccines, gene therapies, and cell-based therapies. They are used in the treatment of various diseases such as cancer, cardiovascular diseases, autoimmune disorders, and genetic conditions. The market encompasses both innovator biologics and biosimilars (copies of innovator biologics), with the growing adoption of biosimilars driving further market growth.

Market Segmentation

For Segmentation Click Here @ https://straitsresearch.com/report/biologics-market/segmentation

Key Segmentation Categories

• By Type: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Gene Therapies, Cell-based Therapies
• By Application: Cancer, Autoimmune Diseases, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases, Others
• By End-User: Hospitals, Research Institutes, Biotechnology Companies, Pharmaceutical Companies
• By Region: North America, Europe, Asia-Pacific, Middle East & Africa, South America

Highlights of Biologics Market

1. The global biologics market size was valued at USD 343 billion in 2021 and is projected to reach USD 506 billion by 2030.
2. The market is expected to grow at a CAGR of 4% from 2022 to 2030.
3. Increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, is driving the demand for biologic therapies.
4. Advancements in biotechnology, including gene therapies and monoclonal antibodies, are shaping the future of biologics.
5. The growing adoption of biosimilars is contributing to market expansion by providing affordable alternatives to expensive innovator biologics.

Key Players

• AbbVie Inc.
• Amgen Inc.
• Roche Holding AG
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Merck & Co., Inc.
• Eli Lilly and Co.
• Regeneron Pharmaceuticals, Inc.

Dominated Region: Asia-Pacific
Fastest Growing Region: Europe

For More Information or Query or Customization Before Buying, Visit @ https://straitsresearch.com/buy-now/biologics-market

7 Questions Answered in the Report

1. What is the current size of the global biologics market?
2. What are the main growth drivers of the biologics market?
3. What types of biologic products are driving market growth?
4. Which regions are expected to experience the highest growth in the biologics market?
5. How do biosimilars contribute to the biologics market?
6. What are the major applications of biologics?
7. What are the leading companies in the biologics market?

Regional Insights

• North America: North America holds a significant share of the biologics market, led by the U.S., where strong healthcare infrastructure, increased demand for biologics in treating chronic conditions, and a robust pipeline of biologic drugs drive market growth.

• Europe: Europe is projected to be the fastest-growing region in the biologics market due to increasing research and development efforts, the approval of new biologics, and the expanding healthcare infrastructure. The adoption of biosimilars is also contributing to this growth.

• Asia-Pacific: The Asia-Pacific region dominates the biologics market, with key growth contributors being China and India. Increasing healthcare access, government initiatives for biotechnology research, and rising demand for biologics are driving this market.

For Full PDF Sample Copy of the Report
Get a Full PDF Sample Copy of the Report @ https://straitsresearch.com/report/biologics-market/request-sample

Conclusion

The global biologics market is experiencing significant growth, driven by advancements in biotechnology, increasing demand for targeted therapies, and the rising prevalence of chronic diseases. The introduction of biosimilars is expected to provide affordable alternatives, further enhancing market growth. As the demand for biologics continues to rise, key players are focusing on expanding their product portfolios and enhancing their R&D capabilities to stay competitive in this rapidly evolving market. With the Asia-Pacific region dominating and Europe witnessing the fastest growth, the biologics market is expected to continue its upward trajectory, providing new opportunities in the treatment of various diseases.

For Custom Report Click Here @ https://straitsresearch.com/buy-now/biologics-market

Contact Us:
Email: sales@straitsresearch.com
Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)